Skip to main content
DrugPrice

Brilinta vs Lovenox

Side-by-side cost comparison based on Medicare Part D data

Lovenox costs 59% less per claim than Brilinta ($94.00 vs $229.00). A generic version of Lovenox is also available, which may reduce costs further.

Cost Per Claim

Brilinta$229.00
Lovenox$94.00

Medicare Spending

Brilinta$567.0M
Lovenox$456.0M

Beneficiaries

Brilinta298,000
Lovenox580,000

Annual Cost Per Patient

Brilinta$1,903.00
Lovenox$786.00

Full Comparison

MetricBrilintaLovenox
Avg Cost Per Claim$229.00$94.00
Total Medicare Spending$567.0M$456.0M
Total Beneficiaries298,000580,000
Total Claims2,480,0004,860,000
Annual Cost/Patient$1,903.00$786.00
Year-over-Year Change-8.4%-14.2%
Generic AvailableYesYes
Patent ExpirationJan 31, 2023Jan 31, 2023
ManufacturerAstraZenecaSanofi
ConditionBlood ClotsBlood Clots
Generic NameTicagrelorEnoxaparin

Brilinta vs Lovenox: What the Data Shows

Brilinta (Ticagrelor) and Lovenox (Enoxaparin) are both used to treat blood clots. Based on Medicare Part D data, Lovenox costs $94.00 per claim, which is 59% less than Brilinta at $229.00 per claim.

Medicare spent $567.0M on Brilinta and $456.0M on Lovenox. In terms of patient reach, Lovenox serves more beneficiaries (580,000 vs 298,000).

Year-over-year spending changed -8.4% for Brilinta and -14.2% for Lovenox.

Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.

Frequently Asked Questions

Lovenox is cheaper at $94.00 per claim, compared to $229.00 for Brilinta. That makes Lovenox about 59% less expensive per claim based on Medicare Part D data.

Yes, both Brilinta and Lovenox are used to treat blood clots. Your doctor can help determine which medication is more appropriate for your specific situation.

Both drugs have generic versions available. Generic Ticagrelor and generic Enoxaparin can offer significant cost savings — typically 80-95% less than the brand name.

Medicare Part D spent $567.0M on Brilinta covering 298,000 beneficiaries, and $456.0M on Lovenox covering 580,000 beneficiaries.

Explore Further

Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.